- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Senate rejects drug-importation proposal
December 16, 2009
IBJ Staff and Associated PressThe U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
MoreLilly wins approval for long-acting Zyprexa
December 14, 2009
J.K. WallOnce-a-month injection of best-selling drug will have patents that could extend until 2018.
MoreEli Lilly's shares slip after it forecasts mixed profits in coming years
December 10, 2009
IBJ Staff and Associated PressThe Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
MoreLilly launching new venture capital fund
December 10, 2009
J.K. WallThe fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's
drug pipeline.
MoreAriad asks court to restore patent-suit win against Lilly
December 8, 2009
IBJ StaffA federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
MoreBuilder looks to cold storage for steady work in a weak economy
December 5, 2009
Brock BenefielCold storage might become a hot business for a building contractor.
MorePart of Mississippi's Zyprexa case against Lilly dismissed
December 2, 2009
IBJ StaffIndianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
MoreLilly extends research pact with India firm
December 1, 2009
IBJ StaffJubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
MoreLilly's Cymbalta wins new approval for anxiety disorder
November 30, 2009
J.K. WallFDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
MoreLilly stock droops after rival claims faster-acting impotence pill
November 18, 2009
IBJ StaffCalifornia-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
MoreLilly to pay Utah $24 million to settle Zyprexa suit
November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
MoreLilly, WellPoint CEOs pin hopes on Senate
November 11, 2009
J.K. WallDrugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
MoreLilly reducing sales force by 191 as part of larger restructuring
November 2, 2009
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring
announced
in September
that ultimately will result in 5,500 job cuts by the end of 2011.
MoreTechPoint to focus on IT firms specializing in medical, life sciences sectors
October 31, 2009
Chris O'MalleyLong tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s
IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing
Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
MoreLilly opens new biotech center in San Diego
October 29, 2009
J.K. WallLilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
MoreLilly to move 1,000 from Faris campus
October 26, 2009
J.K. WallAs it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees
to its corporate
center
by mid-2010.
MoreLilly needs to sell more Effient before Zyprexa loses patent protection
October 24, 2009
J.K. WallSales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The
blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
MoreLilly settles Zyprexa case with S. Carolina for $45M
October 23, 2009
IBJ Staff and Associated PressSouth Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company's marketing of an anti-psychotic drug.
MoreEli Lilly CEO banking on new drug pipeline
October 22, 2009
Associated PressCEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He's betting there will be a fourth.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
MoreUncertainty over drug pipeline sends Lilly shares down
October 21, 2009
J.K. WallFor the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
MoreLilly reports $942 million profit in third quarter
October 21, 2009
J.K. WallExcluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
MoreMedco plans to compare Plavix, Effient in study
October 20, 2009
IBJ Staff and Associated PressMedco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
MoreGerman company to buy Eli Lilly's Lafayette plant
October 17, 2009
J.K. WallEli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing
its work force by 5,500 employees and cutting its operating expenses by $1 billion.
MoreLilly to pay Idaho $13M in drug settlement
October 14, 2009
IBJ Staff and Associated PressIdaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing
of
anti-psychotic drug Zyprexa.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Ameriana Bank took over Westfield Farmers Market for 2013 and it is held in their parking lot, corner of 32 and Carey road, 5 to 8. I am selling soap and candles there. great market!
B&T certainly has enough of our taxpayer dollars to do this thanks to Mayor Ballard. Given the firm's exceedingly poor reputation in the legal community, the basement would seem a better option.
Should read MAY hire 20 people.
Not a good location for a 300,000 home. 10th Street fumes, buses, noise. Max for this location 150,000.
The state constitution also does not say that the majority has a right to quorum, nor that the minority is required to allow them quorum. In fact, denial of quorum has been a parliamentary maneuver since the establishment of the first parliaments in the early 1600s. The right to deny quorum (and the requirement fore quorum) are to prevent exactly what happened in Indiana: A tyrannical majority pushing through odious, objectionable legislation. Denial of quorum is totally legitimate, and lest we forget, a tactic the GOP has employed many, many times to ensure their issues weren't given short shrift. By allowing the majority to impose "fines" on the minority for exercising the authority the constitution grants them (to deny quorum,) they are violating the constitution.